How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet
Centene's robust cash flow is helping cut debt, with a lower debt-to-capital ratio and added liquidity reshaping its balance sheet.
Zacks
How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet
Centene's robust cash flow is helping cut debt, with a lower debt-to-capital ratio and added liquidity reshaping its balance sheet.
Zacks
More News
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
Here is how Elevance Health (ELV) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
Zacks
ELV or DHR: Which Is the Better Value Stock Right Now?
ELV vs. DHR: Which Stock Is the Better Value Option?
Zacks
Here's How CVS' Health Services Arm Is Positioned for Long-Term Growth
CVS Health's Health Services arm is gaining from pharmacy strength and improving care delivery, with robust new sales and clinic economics supporting growth.
Zacks
Can Centene's Medicare Advantage Strategy Unlock Better Margins?
CNC is set to reshape its Medicare Advantage business around dual-eligible members and a simpler footprint to drive margin recovery.
Zacks
Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation
Elevance Health shares are jumping Thursday after the company reaffirmed its FY26 earnings guidance ahead of a series of investor meetings.read more...
Benzinga
UnitedHealth Reshapes Florida WellMed Operations With TPG Deal
UNH's TPG deal brings local support and investment to Florida WellMed clinics as Optum targets faster growth and stronger profitability.
Zacks
UnitedHealth Stock Rises 39% in 6 Months: Should Investors Still Buy?
UNH's 39% six-month rally reflects improving medical costs, stronger earnings estimates and a sharper focus on profitable businesses.
Zacks
Is UnitedHealth Finally Turning the Corner After a Tough 2025?
UNH is showing signs of recovery as medical costs improve, Optum gains momentum and 2026 earnings guidance rises.
Zacks
Centene Stock Roars Back 117% in a Year: Is CNC Still a Buy?
CNC's 117% rally now has support from improving margins, firmer pricing and higher earnings expectations, while valuation remains below key peers.